# The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus

> **NCT06851611** · PHASE1 · COMPLETED · sponsor: **Rokote Laboratories Finland Oy** · enrollment: 40 (actual)

## Conditions studied

- COVID19, Sars-Cov-2

## Interventions

- **BIOLOGICAL:** COVID-19 vaccine, low dose level
- **BIOLOGICAL:** COVID-19 vaccine, high dose level
- **OTHER:** Nasal Drops
- **OTHER:** Nasal Spray

## Key facts

- **NCT ID:** NCT06851611
- **Lead sponsor:** Rokote Laboratories Finland Oy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-21
- **Primary completion:** 2025-06-25
- **Final completion:** 2025-06-26
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06851611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06851611, "The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06851611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*